

Corporate Action Notice

July 19, 2018

Name Change

Ratio Change and Stock Distribution

Kingboard Chemical Holdings Limited

DR CUSIP: 49566C106 / DR ISIN: US49566C1062

DR Ticker Symbol: KBDCY

Ratio (DRs: Underlying Shares): 1:10

Please be advised that Kingboard Chemical Holdings Limited announced a name change **to Kingboard Holdings Limited**. The current CUSIP number(s) and Ticker Symbol(s) will remain the same.

Immediately after the name change, BNY Mellon, as Depositary, will change the ratio on the Kingboard Holdings Limited Depositary Receipt ("DR") program from one (1) Depositary Receipt ("DR") representing ten (10) Ordinary shares to a new ratio of one (1) DR representing five (5) Ordinary shares. .

The ratio change will occur simultaneously with a 100% DS distribution (1 additional DS for each DS held).

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for cancellations from the close of business July 30, 2018. The books were closed for issuances on July 17, 2018. It is anticipated that the books will reopen for issuances and cancellations on August 3, 2018.

BNY MELLON HAS ESTABLISHED THE FOLLOWING DATES FOR THIS CORPORATE ACTION:

DR Effective Date of Name Change: July 31, 2018

DR Record Date:	July 30, 2018
DR Payable Date:	July 31, 2018
DR Effective Date:	July 31, 2018
DR Distribution Rate:	100%
Issuance Fee:	\$0.00
Old Ratio:	1 DR : 10 Ordinary Shares
New Ratio:	1 DR : 5 Ordinary Shares

First day of trading under the new ratio is expected to be August 1, 2018.

To learn more about Depositary Receipts and issuer programs, please contact DR Broker Solutions:

NEW YORK & LONDON
adrdesk@bnymellon.com

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon, and are subject to investment risks.

